181 related articles for article (PubMed ID: 38441386)
41. Adenovirus-Mediated Gene Delivery: Potential Applications for Gene and Cell-Based Therapies in the New Era of Personalized Medicine.
Lee CS; Bishop ES; Zhang R; Yu X; Farina EM; Yan S; Zhao C; Zheng Z; Shu Y; Wu X; Lei J; Li Y; Zhang W; Yang C; Wu K; Wu Y; Ho S; Athiviraham A; Lee MJ; Wolf JM; Reid RR; He TC
Genes Dis; 2017 Jun; 4(2):43-63. PubMed ID: 28944281
[TBL] [Abstract][Full Text] [Related]
42. Cholesterol-rich lipid-mediated nanoparticles boost of transfection efficiency, utilized for gene editing by CRISPR-Cas9.
Hosseini ES; Nikkhah M; Hosseinkhani S
Int J Nanomedicine; 2019; 14():4353-4366. PubMed ID: 31354265
[No Abstract] [Full Text] [Related]
43. Cell-derived extracellular vesicles for CRISPR/Cas9 delivery: engineering strategies for cargo packaging and loading.
Liang Y; Iqbal Z; Wang J; Xu L; Xu X; Ouyang K; Zhang H; Lu J; Duan L; Xia J
Biomater Sci; 2022 Jul; 10(15):4095-4106. PubMed ID: 35766814
[TBL] [Abstract][Full Text] [Related]
44. Barriers to non-viral vector-mediated gene delivery in the nervous system.
Pérez-Martínez FC; Guerra J; Posadas I; Ceña V
Pharm Res; 2011 Aug; 28(8):1843-58. PubMed ID: 21225319
[TBL] [Abstract][Full Text] [Related]
45. In Vitro Transduction and Target-Mutagenesis Efficiency of HIV-1 pol Gene Targeting ZFN and CRISPR/Cas9 Delivered by Various Plasmids and/or Vectors: Toward an HIV Cure.
Okee M; Bayiyana A; Musubika C; Joloba ML; Ashaba-Katabazi F; Bagaya B; Wayengera M
AIDS Res Hum Retroviruses; 2018 Jan; 34(1):88-102. PubMed ID: 29183134
[TBL] [Abstract][Full Text] [Related]
46. Current status of non-viral gene therapy for CNS disorders.
Jayant RD; Sosa D; Kaushik A; Atluri V; Vashist A; Tomitaka A; Nair M
Expert Opin Drug Deliv; 2016 Oct; 13(10):1433-45. PubMed ID: 27249310
[TBL] [Abstract][Full Text] [Related]
47. Exosome/Liposome-like Nanoparticles: New Carriers for CRISPR Genome Editing in Plants.
Alghuthaymi MA; Ahmad A; Khan Z; Khan SH; Ahmed FK; Faiz S; Nepovimova E; Kuča K; Abd-Elsalam KA
Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299081
[TBL] [Abstract][Full Text] [Related]
48. Applications and Research Advances in the Delivery of CRISPR/Cas9 Systems for the Treatment of Inherited Diseases.
Lu X; Zhang M; Li G; Zhang S; Zhang J; Fu X; Sun F
Int J Mol Sci; 2023 Aug; 24(17):. PubMed ID: 37686009
[TBL] [Abstract][Full Text] [Related]
49. Highly multiplex guide RNA expression units of CRISPR/Cas9 were completely stable using cosmid amplification in a novel polygonal structure.
Nakanishi T; Maekawa A; Tabata H; Yoshioka T; Pei Z; Sato K; Mori M; Kato M; Saito I
J Gene Med; 2019 Nov; 21(11):e3115. PubMed ID: 31348845
[TBL] [Abstract][Full Text] [Related]
50. Hyperbranched polymeric "star vectors" for effective DNA or siRNA delivery.
Nakayama Y
Acc Chem Res; 2012 Jul; 45(7):994-1004. PubMed ID: 22353143
[TBL] [Abstract][Full Text] [Related]
51. Current Designs of Polymeric Platforms Towards the Delivery of Nucleic Acids Inside the Cells with Focus on Polyethylenimine.
de Oliveira FA; Albuquerque LJC; Delecourt G; Bennevault V; Guégan P; Giacomelli FC
Curr Gene Ther; 2021; 21(5):431-451. PubMed ID: 34225620
[TBL] [Abstract][Full Text] [Related]
52. Non-Viral Vector-Mediated Gene Therapy for ALS: Challenges and Future Perspectives.
Ediriweera GR; Chen L; Yerbury JJ; Thurecht KJ; Vine KL
Mol Pharm; 2021 Jun; 18(6):2142-2160. PubMed ID: 34010004
[TBL] [Abstract][Full Text] [Related]
53. Gene therapy of cancer.
Rochlitz CF
Swiss Med Wkly; 2001 Jan; 131(1-2):4-9. PubMed ID: 11205184
[TBL] [Abstract][Full Text] [Related]
54. A novel non-viral delivery method that enables efficient engineering of primary human T cells for ex vivo cell therapy applications.
Kavanagh H; Dunne S; Martin DS; McFadden E; Gallagher L; Schwaber J; Leonard S; O'Dea S
Cytotherapy; 2021 Sep; 23(9):852-860. PubMed ID: 33941482
[TBL] [Abstract][Full Text] [Related]
55. Nanosystems for gene therapy targeting brain damage caused by viral infections.
da Silva TN; de Lima EV; Barradas TN; Testa CG; Picciani PHS; Figueiredo CP; do Carmo FA; Clarke JR
Mater Today Bio; 2023 Feb; 18():100525. PubMed ID: 36619201
[TBL] [Abstract][Full Text] [Related]
56. Invasive drug delivery.
Blömer U; Ganser A; Scherr M
Adv Exp Med Biol; 2002; 513():431-51. PubMed ID: 12575831
[TBL] [Abstract][Full Text] [Related]
57. Key considerations in designing CRISPR/Cas9-carrying nanoparticles for therapeutic genome editing.
Xu Y; Liu R; Dai Z
Nanoscale; 2020 Oct; 12(41):21001-21014. PubMed ID: 33078813
[TBL] [Abstract][Full Text] [Related]
58. Overcoming the delivery problem for therapeutic genome editing: Current status and perspective of non-viral methods.
Mashel TV; Tarakanchikova YV; Muslimov AR; Zyuzin MV; Timin AS; Lepik KV; Fehse B
Biomaterials; 2020 Nov; 258():120282. PubMed ID: 32798742
[TBL] [Abstract][Full Text] [Related]
59. Nanotechnology-based non-viral vectors for gene delivery in cardiovascular diseases.
Jiao L; Sun Z; Sun Z; Liu J; Deng G; Wang X
Front Bioeng Biotechnol; 2024; 12():1349077. PubMed ID: 38303912
[TBL] [Abstract][Full Text] [Related]
60. Successful delivery of large-size CRISPR/Cas9 vectors in hard-to-transfect human cells using small plasmids.
Søndergaard JN; Geng K; Sommerauer C; Atanasoai I; Yin X; Kutter C
Commun Biol; 2020 Jun; 3(1):319. PubMed ID: 32561814
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
